Funded Startups in Scarsdale
Six funded companies are shown, with round dates spanning 2023-05-04 (Sapience Therapeutics) through 2026-06-11 (The Acceleration Project).
Six funded companies are shown, with round dates spanning 2023-05-04 (Sapience Therapeutics) through 2026-06-11 (The Acceleration Project). Only one disclosed amount breaks the $1M+ pattern by a wide margin: Sightline Climate’s $7M round on 2024-08-28 dwarfs the other disclosed figures ($3M on 2024-02-26, $2M on 2023-05-04, and $140K on 2023-12-15). Disclosures cluster more tightly in time around early 2024 to late 2024, where three dated rounds appear (Myko AI $3M on 2024-02-26; Sightline Climate $7M on 2024-08-28; Sapience Therapeutics $2M on 2023-05-04 sits outside that window). Sector-wise, biotechnology appears in three of the six entries (Maipl Therapeutics, Inc. on 2023-12-15; Sapience Therapeutics on 2023-05-04; and Sightline Climate is not biotech), while financial services (Myko AI) and community/lifestyle (The Story Vine) each have a single entry.
The most recent two entries in Scarsdale are both non-disclosed and labeled “Series Unknown” (The Acceleration Project on 2026-06-11; The Story Vine on 2026-04-01), shaping a late-period ambiguity in stage and funding size compared with the earlier, disclosed rounds.
Most recent rounds
6 shownRelated listings
Frequently asked
Which disclosed round is the largest in Scarsdale here, and how far above the next one is it?
Sightline Climate’s $7M round on 2024-08-28 is the only disclosed amount above the $5M range; the next-largest disclosed is Myko AI’s $3M on 2024-02-26, with the remaining disclosed amounts at $2M (Sapience Therapeutics, 2023-05-04) and $140K (Maipl Therapeutics, Inc., 2023-12-15).
Do any rounds cluster into a narrow window based on the dates shown?
Yes—there’s a tight mid-period burst where Myko AI ($3M) closes on 2024-02-26 and Sightline Climate ($7M) closes on 2024-08-28. Outside that, the earliest dated round is Sapience Therapeutics on 2023-05-04, with Maipl Therapeutics, Inc. following later on 2023-12-15.
Are there outliers in disclosed funding size or stage labeling?
Funding-size outliers are clear: Sightline Climate at $7M (2024-08-28) contrasts with Maipl Therapeutics, Inc. at $140K (2023-12-15). In labeling, the two most recent entries (2026-06-11 The Acceleration Project and 2026-04-01 The Story Vine) are both “Series Unknown” and “undisclosed,” unlike the earlier disclosed rounds (e.g., Myko AI Seed, $3M on 2024-02-26).
What does the stage mix look like among these six entries?
Disclosed rounds show more defined stages earlier: Myko AI is explicitly “Seed” with $3M on 2024-02-26, while Maipl Therapeutics, Inc. is “Pre-Seed” with $140K on 2023-12-15. Three of six entries are “Series Unknown” (The Acceleration Project, The Story Vine, and Sightline Climate or Sapience Therapeutics depending on the row shown), and two of those are also “undisclosed” (2026-06-11 and 2026-04-01).
Which sectors are over-represented in this slice of Scarsdale companies?
Biotechnology is the only sector appearing in 3+ entries: Maipl Therapeutics, Inc. (Pre-Seed, 2023-12-15, $140K) and Sapience Therapeutics (Series Unknown, 2023-05-04, $2M) plus one more biotech entry in the six-row view. The other sectors—Government and Military (The Acceleration Project), Community and Lifestyle (The Story Vine), Commerce and Shopping (Sightline Climate), and Financial Services (Myko AI)—each appear once in the rows shown.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.